论文部分内容阅读
目的分析通心络胶囊治疗急性缺血性脑卒中的疗效及安全性。方法将65例急性缺血性脑卒中患者随机分为甲组37例和乙组38例,甲组给予基础治疗,乙组在甲组治疗的基础上应用通心络胶囊进行治疗,对临床疗效和安全性进行分析。结果乙组总有效率为89.5%高于甲组的67.6%,差异有统计学意义(P<0.05)。乙组不良反应率为5.3%低于甲组的10.8%,差异有统计学意义(P<0.05)。结论对急性缺血性脑卒中患者应用通心络胶囊进行治疗,能缓解患者神经功能损伤症状,整体优势明显,值得推广和应用。
Objective To analyze the efficacy and safety of Tongxinluo capsule in the treatment of acute ischemic stroke. Methods A total of 65 patients with acute ischemic stroke were randomly divided into group A (37 cases) and group B (38 cases). Group A received basic treatment. Group B received Tongxinluo capsule for treatment based on group A, and clinical efficacy And security analysis. Results The total effective rate in group B was 89.5%, which was higher than 67.6% in group A, the difference was statistically significant (P <0.05). Adverse reaction rate in group B was 5.3%, lower than that in group A (10.8%), the difference was statistically significant (P <0.05). Conclusion The application of Tongxinluo capsule in patients with acute ischemic stroke can relieve the symptoms of neurological injury in patients with obvious overall advantages and is worthy of popularization and application.